Literature DB >> 8403515

Peri-operative modulation of cellular immunity in patients with colorectal cancer.

P H Nichols1, C W Ramsden, U Ward, L K Trejdosiewicz, N S Ambrose, J N Primrose.   

Abstract

The peri-operative cellular immune response is depressed in patients with gastrointestinal cancer, a factor which may facilitate malignant dissemination. We have investigated the effects of peri-operative rIL-2 and a combination of rIL-2 and interferon-alpha (IFN-alpha) on both peripheral blood lymphocyte function and number in patients undergoing surgical resection for colorectal cancer. Fifty-two patients were randomly allocated to either control, rIL-2 or rIL-2 with IFN-alpha treatment arms. In vitro studies were performed pre-operatively and on post-operative days 1, 4, 7 and 10. Natural killer (NK) and lymphokine-activated killer (LAK) cell function were profoundly depressed in control patients (P < 0.001; P < 0.01), an effect abrogated in both treatment groups; indeed NK function was augmented in the rIL-2 and IFN-alpha group on the first post-operative day in association with an increase in the percentage of cells expressing CD16 and CD56 (P < 0.01). Flow cytometric analysis of lymphocyte subsets in the control group was unremarkable, except for an early post-operative fall in numbers of lymphocytes. Treatment with either rIL-2 or rIL-2 and IFN-alpha produced an initial profound reduction in T lymphocyte numbers, followed by a 'rebound' lymphocytosis of activated CD3+ T cells, as demonstrated by a significant increase in co-expression of CD25, CD38 and CD45RO. No significant differences were observed between either of the treatment groups. Adjuvant immunotherapy affects peri-operative anti-tumour immune responses, and this may influence long term outcome in patients undergoing surgery for gastrointestinal cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8403515      PMCID: PMC1534352          DOI: 10.1111/j.1365-2249.1993.tb05968.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Immunodepression after major surgery in normal patients.

Authors:  M S Slade; R L Simmons; E Yunis; L J Greenberg
Journal:  Surgery       Date:  1975-09       Impact factor: 3.982

2.  CIRCULATING CANCER CELLS DURING EXCISION OF CARINOMAS OF THE RECTUM AND COLON WITH HIGH LIGATION OF THE INFERIOR MESENTERIC VEIN.

Authors:  A J SALSBURY; J A MCKINNA; J D GRIFFITHS; C N MORGAN
Journal:  Surg Gynecol Obstet       Date:  1965-06

Review 3.  Interferon therapy in cancer: from imaginon to interferon.

Authors:  D Goldstein; J Laszlo
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

4.  Cytotoxic reactivity of human lymphocytes cultured in vitro.

Authors:  J R Ortaldo; G D Bonnard; R B Herberman
Journal:  J Immunol       Date:  1977-10       Impact factor: 5.422

5.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

6.  The influence of surgical operations on components of the human immune system.

Authors:  T W Lennard; B K Shenton; A Borzotta; P K Donnelly; M White; L M Gerrie; G Proud; R M Taylor
Journal:  Br J Surg       Date:  1985-10       Impact factor: 6.939

7.  Decreased interleukin-2 production in patients with gastrointestinal cancer.

Authors:  J R Monson; C Ramsden; P J Guillou
Journal:  Br J Surg       Date:  1986-06       Impact factor: 6.939

8.  Prevention of growth of metastases in rat liver by perioperative immunoactivation.

Authors:  R Yamashita; T Hiraoka; I Kamimoto; Y Miyauchi
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

9.  Halothane, surgery, immunosuppression and artificial pulmonary metastases.

Authors:  J Lundy; E J Lovett; S Hamilton; P Conran
Journal:  Cancer       Date:  1978-03       Impact factor: 6.860

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  7 in total

1.  Perioperative cimetidine application modulates natural killer cells in patients with colorectal cancer: a randomized clinical study.

Authors:  D Bai; G Yang; H Yuan; Y Li; K Wang; H Shao
Journal:  J Tongji Med Univ       Date:  1999

2.  Levels of lymphocyte subsets in peripheral blood prior treatment are associated with aggressive breast cancer phenotypes or subtypes.

Authors:  Yijun Jia; Lei Xu; Qing Lin; Mingjie Zhu; Longlong Ding; Kejin Wu; Yunshu Lu
Journal:  Med Oncol       Date:  2014-05-06       Impact factor: 3.064

3.  Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity.

Authors:  Lee-Hwa Tai; Almohanad A Alkayyal; Amanda L Leslie; Shalini Sahi; Sean Bennett; Christiano Tanese de Souza; Katherine Baxter; Leonard Angka; Rebecca Xu; Michael A Kennedy; Rebecca C Auer
Journal:  Oncoimmunology       Date:  2018-03-01       Impact factor: 8.110

4.  Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.

Authors:  Jiqing Zhang; Lee-Hwa Tai; Carolina S Ilkow; Almohanad A Alkayyal; Abhirami A Ananth; Christiano Tanese de Souza; Jiahu Wang; Shalini Sahi; Lundi Ly; Charles Lefebvre; Theresa J Falls; Kyle B Stephenson; Ahmad B Mahmoud; Andrew P Makrigiannis; Brian D Lichty; John C Bell; David F Stojdl; Rebecca C Auer
Journal:  Mol Ther       Date:  2014-04-03       Impact factor: 11.454

Review 5.  Dysfunctional Natural Killer Cells in the Aftermath of Cancer Surgery.

Authors:  Leonard Angka; Sarwat T Khan; Marisa K Kilgour; Rebecca Xu; Michael A Kennedy; Rebecca C Auer
Journal:  Int J Mol Sci       Date:  2017-08-17       Impact factor: 5.923

Review 6.  Adjuvant therapy for completely resected stage II colon cancer.

Authors:  Alvaro Figueredo; Megan E Coombes; Som Mukherjee
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

Review 7.  Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines.

Authors:  Lee-Hwa Tai; Rebecca Auer
Journal:  Front Oncol       Date:  2014-08-12       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.